Tags

Type your tag names separated by a space and hit enter

Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
J Gastroenterol Hepatol. 2018 Feb; 33(2):443-452.JG

Abstract

BACKGROUND AND AIMS

Rifaximin is a minimally absorbed antibiotic, which has shown efficacy in irritable bowel syndrome (IBS) patients. However, the mechanism on how it effects in IBS is still incompletely defined. In this study, Trichinella spiralis-infected post-infectious (PI) IBS mouse model was used, to assess the action of rifaximin on visceral hypersensitivity, barrier function, gut inflammation, and microbiota.

METHODS

Post-infectious IBS model was established by T. spiralis infection in mice. Rifaximin were administered to PI-IBS mice for seven consecutive days. The abdominal withdrawal reflex and threshold of colorectal distention were employed to evaluate visceral sensitivity. Smooth muscle contractile response was recorded in the organ bath. Intestinal permeability was measured by Ussing chamber. Expression of tight junction protein and cytokines were measured by Western blotting. Ilumina miseq platform was used to analyze bacterial 16S ribosomal RNA.

RESULTS

Post-infectious IBS mice treated with rifaximin exhibited decreased abdominal withdrawal reflex score, increased threshold, reduced contractile response, and intestinal permeability. Rifaximin also suppressed the expression of interleukin-12 and interleukin-17 and promoted the expression of the major tight junction protein occludin. Furthermore, rifaximin did not change the composition and diversity, and the study reavealed that rifaximin had a tiny effect on the relative abundance of Lactobacillus and Bifidobacterium in this PI-IBS model.

CONCLUSIONS

Rifaximin alleviated visceral hypersensitivity, recovered intestinal barrier function, and inhibited low-grade inflammation in colon and ileum of PI-IBS mouse model. Moreover, rifaximin exerts anti-inflammatory effects with only a minimal effect on the overall composition and diversity of the gut microbiota in this model.

Links

Aggregator Full Text

Authors+Show Affiliations

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

MeSH

AnimalsAnti-Infective AgentsBifidobacteriumDisease Models, AnimalGastrointestinal MicrobiomeInterleukin-12Interleukin-17Irritable Bowel SyndromeLactobacillusMaleMiceOccludinRifamycinsRifaximinTrichinella spiralisTrichinellosis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28573746

Citation

Jin, Yu, et al. "Beneficial Effects of Rifaximin in Post-infectious Irritable Bowel Syndrome Mouse Model Beyond Gut Microbiota." Journal of Gastroenterology and Hepatology, vol. 33, no. 2, 2018, pp. 443-452.

Jin Y, Ren X, Li G, et al. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018;33(2):443-452.

Jin, Y., Ren, X., Li, G., Li, Y., Zhang, L., Wang, H., Qian, W., & Hou, X. (2018). Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. Journal of Gastroenterology and Hepatology, 33(2), 443-452. https://doi.org/10.1111/jgh.13841

Jin Y, et al. Beneficial Effects of Rifaximin in Post-infectious Irritable Bowel Syndrome Mouse Model Beyond Gut Microbiota. J Gastroenterol Hepatol. 2018;33(2):443-452. PubMed PMID: 28573746.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. AU - Jin,Yu, AU - Ren,Xiaoyang, AU - Li,Gangping, AU - Li,Ying, AU - Zhang,Lei, AU - Wang,Huan, AU - Qian,Wei, AU - Hou,Xiaohua, PY - 2016/12/14/received PY - 2017/05/23/revised PY - 2017/05/30/accepted PY - 2017/6/3/pubmed PY - 2018/6/8/medline PY - 2017/6/3/entrez KW - anti-inflammatory effect KW - barrier function KW - gut microbiota KW - irritable bowel syndrome KW - rifaximin SP - 443 EP - 452 JF - Journal of gastroenterology and hepatology JO - J Gastroenterol Hepatol VL - 33 IS - 2 N2 - BACKGROUND AND AIMS: Rifaximin is a minimally absorbed antibiotic, which has shown efficacy in irritable bowel syndrome (IBS) patients. However, the mechanism on how it effects in IBS is still incompletely defined. In this study, Trichinella spiralis-infected post-infectious (PI) IBS mouse model was used, to assess the action of rifaximin on visceral hypersensitivity, barrier function, gut inflammation, and microbiota. METHODS: Post-infectious IBS model was established by T. spiralis infection in mice. Rifaximin were administered to PI-IBS mice for seven consecutive days. The abdominal withdrawal reflex and threshold of colorectal distention were employed to evaluate visceral sensitivity. Smooth muscle contractile response was recorded in the organ bath. Intestinal permeability was measured by Ussing chamber. Expression of tight junction protein and cytokines were measured by Western blotting. Ilumina miseq platform was used to analyze bacterial 16S ribosomal RNA. RESULTS: Post-infectious IBS mice treated with rifaximin exhibited decreased abdominal withdrawal reflex score, increased threshold, reduced contractile response, and intestinal permeability. Rifaximin also suppressed the expression of interleukin-12 and interleukin-17 and promoted the expression of the major tight junction protein occludin. Furthermore, rifaximin did not change the composition and diversity, and the study reavealed that rifaximin had a tiny effect on the relative abundance of Lactobacillus and Bifidobacterium in this PI-IBS model. CONCLUSIONS: Rifaximin alleviated visceral hypersensitivity, recovered intestinal barrier function, and inhibited low-grade inflammation in colon and ileum of PI-IBS mouse model. Moreover, rifaximin exerts anti-inflammatory effects with only a minimal effect on the overall composition and diversity of the gut microbiota in this model. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/28573746/Beneficial_effects_of_Rifaximin_in_post_infectious_irritable_bowel_syndrome_mouse_model_beyond_gut_microbiota_ L2 - https://doi.org/10.1111/jgh.13841 DB - PRIME DP - Unbound Medicine ER -